Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: A call to action

Diabetes Care

Volumn 40, Issue 3, 2017, Pages 419-430

  Bril, Fernando ^a   Cusi, Kenneth ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b Malcom Randall Veterans Affairs Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CYTOKERATIN 18; FIBROBLAST GROWTH FACTOR 21; LIRAGLUTIDE; OBETICHOLIC ACID; PIOGLITAZONE; PLACEBO; TELMISARTAN; VALSARTAN;

ALGORITHM; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BARD SCORE; BLADDER CANCER; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTROLLED ATTENUATION PARAMETER; DIAGNOSTIC PROCEDURE; DYSLIPIDEMIA; ECHOGRAPHY; ELASTOGRAPHY; FATTY LIVER INDEX; FIBROSIS 4 INDEX; HISTOLOGY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER FUNCTION TEST; MAGNETIC RESONANCE ELASTOGRAPHY; NAFIC SCORE; NAFLD FIBROSIS SCORE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SIDE EFFECT; SMOKING; WEIGHT GAIN; CARCINOMA, HEPATOCELLULAR; COMPLICATION; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; LIFESTYLE; LIVER NEOPLASMS; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

CARCINOMA, HEPATOCELLULAR; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; HYPERGLYCEMIA; LIFE STYLE; LIVER NEOPLASMS; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 85019660310     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-1787     Document Type: Review

References (120)

1. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013;10: 686-690
2. Rinella ME. Nonalcoholic fatty liver disease: A systematic review. JAMA 2015;313:2263-2273
3. Chalasani N, Younossi Z, Lavine JE, et al.; American Gastroenterological Association; American Association for the Study of Liver Diseases; American College of Gastroenterology. The diagnosis and management of nonalcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012;142:1592-1609
4. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-Alcoholic fatty liver disease. Diabetologia 2016;59:1121-1140
5. Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-Alcoholic fatty liver disease and diabetes. Metabolism 2016;65:1096-1108
6. Koliaki C, Roden M. Hepatic energy metabolism in human diabetes mellitus, obesity and non-Alcoholic fatty liver disease. Mol Cell Endocrinol 2013;379:35-42
7. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-468
8. Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: A systematic review and metaanalysis of cohort studies. Int J Cancer 2012; 130:1639-1648
9. Lomonaco R, Bril F, Portillo-Sanchez P, et al. Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes. Diabetes Care 2016;39:632-638
10. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012;142:711-725.e6
11. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA 2015;314:1021-1029
12. Pais R, Charlotte F, Fedchuk L, et al.; LIDO Study Group. A systematic review of follow-up biopsies reveals disease progression in patients with non-Alcoholic fatty liver. J Hepatol 2013; 59:550-556
13. Rinella ME, Lominadze Z, Loomba R, et al. Practice patterns in NAFLD and NASH: real life differs from published guidelines. Therap Adv Gastroenterol 2016;9:4-12
14. Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-Alcoholic fatty liver disease. J Hepatol 2004;40:578-584
15. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015;148:547-555
16. Bugianesi E, Vanni E, Marchesini G.NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Curr Diab Rep 2007;7:175-180
17. Ortiz-Lopez C, Lomonaco R, Orsak B, et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care 2012; 35:873-878
18. Bril F, Sninsky JJ, Baca AM, et al. Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD. J Clin Endocrinol Metab 2016;101:644-652
19. Siddiqui MS, Fuchs M, Idowu MO, et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clin Gastroenterol Hepatol 2015;13:1000-1008.e3
20. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008;134: 424-431
21. Bril F, Lomonaco R, Orsak B, et al. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology 2014;59:2178-2187
22. Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007;30:2119-2121
23. Musso G, Gambino R, Tabibian JH, et al. Association of non-Alcoholic fatty liver disease with chronic kidney disease: A systematic review and meta-Analysis. PLoS Med 2014;11: e1001680
24. IoannouGN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol 2006;101:76-82
25. Forlani G, Giorda C, Manti R, et al. The burden of NAFLD and its characteristics in a nationwide population with type 2 diabetes. J Diabetes Res 2016;2016:2931985
26. Tota-Maharaj R, Blaha MJ, Zeb I, et al. Ethnic and sex differences in fatty liver on cardiac computed tomography: The multi-ethnic study of atherosclerosis. Mayo Clin Proc 2014;89:493-503
27. McKimmie RL, Daniel KR, Carr JJ, et al. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: The Diabetes Heart Study. Am J Gastroenterol 2008;103:3029-3035
28. Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: The Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013;178:38-45
29. Williamson RM, Price JF, Glancy S, et al.; Edinburgh Type 2 Diabetes Study Investigators. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Diabetes Care 2011;34:1139-1144
30. Carvalhana S, Leitão J, Alves AC, Bourbon M, Cortez-Pinto H. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound. Liver Int 2014;34: e111-e117
31. Kwok R, Choi KC, Wong GL, et al. Screening diabetic patients for non-Alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: A prospective cohort study. Gut 2016;65:1359-1368
32. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-1395
33. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-Alcoholic fatty liver disease. J Hepatol 2008; 49:608-612
34. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137:1-10
35. Portillo-Sanchez P, Bril F, Maximos M, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab 2015;100:2231-2238
36. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-Aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology 2011;140:124-131
37. Hepburn MJ, Vos JA, Fillman EP, Lawitz EJ. The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: A retrospective observational study. BMC Gastroenterol 2005; 5:14
38. Kim SH, Lee JM, Kim JH, et al. Appropriateness of a donor liver with respect to macrosteatosis: Application of artificial neural networks to US imagesdinitial experience. Radiology 2005; 234:793-803
39. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-Analysis. Hepatology 2011;54:1082-1090
40. Bril F, Ortiz-Lopez C, Lomonaco R, et al. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver Int 2015;35:2139-2146
41. Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:33
42. Cuthbertson DJ, Weickert MO, Lythgoe D, et al. External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. Eur J Endocrinol 2014;171:561-569
43. Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V; LIDO Study Group. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014;40: 1209-1222
44. Noureddin M, Lam J, Peterson MR, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013;58:1930-1940
45. Lin SC, Heba E, Wolfson T, et al. Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat using a new quantitative ultrasound technique. Clin Gastroenterol Hepatol 2015;13:1337-1345.e6
46. Poynard T, Lebray P, Ingiliz P, et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol 2010;10:40
47. Perazzo H, Munteanu M, Ngo Y, et al.; FLIP Consortium. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia. Aliment Pharmacol Ther 2014;40:1081-1093
48. Long MT, Pedley A, Massaro JM, Hoffmann U, Fox CS. The association between non-invasive hepatic fibrosis markers and cardiometabolic risk factors in the Framingham Heart Study. PLoS One 2016;11:e0157517
49. Koehler EM, Plompen EP, Schouten JN, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. Hepatology 2016;63:138-147
50. Hossain N, Afendy A, Stepanova M, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7:1224-1229.e1-2.
51. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: A longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42:132-138
52. Bazick J, Donithan M, Neuschwander-Tetri BA, et al. Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD. Diabetes Care 2015;38:1347-1355
53. Castera L. Noninvasive evaluation of nonalcoholic fatty liver disease. Semin Liver Dis 2015;35:291-303
54. Cusi K, Chang Z, Harrison S, et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with nonalcoholic fatty liver disease. J Hepatol 2014;60: 167-174
55. Dumas ME, Kinross J, Nicholson JK. Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease. Gastroenterology 2014;146:46-62
56. Luukkonen PK, Zhou Y, Sädevirta S, et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-Alcoholic fatty liver disease. J Hepatol 2016;64:1167-1175
57. Yki-Järvinen H. Diagnosis of non-Alcoholic fatty liver disease (NAFLD). Diabetologia 2016; 59:1104-1111
58. Doycheva I, Cui J, Nguyen P, et al. Noninvasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther 2016;43:83-95
59. Imajo K, Kessoku T, Honda Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 2016;150:626-637.e7
60. Cusi K, Orsak B, Bril F, et al. Long-Term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial. Ann Intern Med 2016;165:305-315
61. Armstrong MJ, Gaunt P, Aithal GP, et al.; LEAN trial team. Liraglutide safety and efficacy in patients with non-Alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016;387:679-690
62. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al.; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-Alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebocontrolled trial. Lancet 2015;385:956-965
63. Hannah WN Jr, Harrison SA. Lifestyle and dietary interventions in the management of nonalcoholic fatty liver disease. Dig Dis Sci 2016;61:1365-1374
64. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121-129
65. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149:367-378.e5
66. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-Analysis. Clin Gastroenterol Hepatol 2008;6:1396-1402
67. Lassailly G, Caiazzo R, Buob D, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis inmorbidly obese patients. Gastroenterology 2015;149:379-388
68. Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the long-Term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009;137:532-540
69. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-Alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010 (1):CD007340
70. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009;49:80-86
71. Bacchi E, Negri C, Targher G, et al. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). Hepatology 2013;58:1287-1295
72. Kirk E, Reeds DN, Finck BN, Mitra MS, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 2009; 136:1552-1560
73. Haufe S, Engeli S, Kast P, et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology 2011;53:1504-1514
74. Bril F, Ntim K, Lomonaco R, Cusi K. Treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). In International Textbook of Diabetes Mellitus. 4th ed. DeFronzo RA, Ferrannini E, Alberti KGMM, Zimmet P, Eds. Chichester, U.K., John Wiley & Sons Ltd., 2015, p. 292-305
75. Bril F, Maximos M, Portillo-Sanchez P, et al. Relationship of vitamin D with insulin resistance and disease severity in non-Alcoholic steatohepatitis. J Hepatol 2015;62:405-411
76. Argo CK, Patrie JT, Lackner C, et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trial. J Hepatol 2015;62: 190-197
77. Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator-Activated receptor-Alpha and-delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 2016;150:1147-1159.e5
78. Sanyal AJ, Chalasani N, Kowdley KV, et al.; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-1685
79. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307
80. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135: 1176-1184
81. Zein CO, Yerian LM, Gogate P, et al. Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial. Hepatology 2011;54:1610-1619
82. Sanyal AJ, Ratziu V, Harrison S, et al. Cenicriviroc placebo for the treatment of nonalcoholic steatohepatitis with liver fibrosis: results from the Year 1 primary analysis of the Phase 2b CENTAUR study (Abstract). Hepatology 2016;64:1118A
83. Yau H, Rivera K, Lomonaco R, Cusi K. The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diab Rep 2013;13:329-341
84. Gastaldelli A, Harrison SA, Belfort-Aguilar R, et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 2009; 50:1087-1093
85. Gastaldelli A, Harrison S, Belfort-Aguiar R, et al. Pioglitazone in the treatment of NASH: The role of adiponectin. Aliment Pharmacol Ther 2010;32:769-775
86. Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007;46:424-429
87. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A metaanalysis of randomized trials. JAMA 2007;298: 1180-1188
88. Dormandy JA, Charbonnel B, Eckland DJ, et al.; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005;366:1279-1289
89. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: A randomized trial. JAMA 2006;296:2572-2581
90. Nissen SE, Nicholls SJ, Wolski K, et al.; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial. JAMA 2008;299:1561-1573
91. Kernan WN, Viscoli CM, Furie KL, et al.; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016;374:1321-1331
92. DeFronzo RA, Tripathy D, Schwenke DC, et al.; ACT NOWStudy. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364:1104-1115
93. Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ 2016;352:i1541
94. Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 2015;314:265-277
95. Hamaguchi E, Takamura T, Sakurai M, et al. Histological course of nonalcoholic fatty liver disease in Japanese patients: Tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care 2010;33:284-286
96. Juurinen L, Tiikkainen M, Häkkinen AM, Hakkarainen A, Yki-Järvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2007;292:E829-E835
97. Leiter LA, Forst T, Polidori D, Balis DA, Xie J, Sha S. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab 2016;42:25-32
98. Targher G, Bertolini L, Chonchol M, et al. Non-Alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia 2010;53: 1341-1348
99. Bril F, Lomonaco R, Cusi K. The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease. Clin Lipidol 2012;7: 471-481
100. Blais P, Lin M, Kramer JR, El-Serag HB, Kanwal F. Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia. Dig Dis Sci 2016;61:1714-1720
101. Chalasani N, Aljadhey H, Kesterson J, MurrayMD, Hall SD. Patientswith elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287-1292
102. Dongiovanni P, Petta S, Mannisto V, et al. Statin use and non-Alcoholic steatohepatitis in at risk individuals. J Hepatol 2015;63:705-712
103. Szendroedi J, Anderwald C, Krssak M, et al. Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients. Diabetes Care 2009;32:209-214
104. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. J Clin Gastroenterol 2009;43:990-994
105. Ginsberg HN, Elam MB, Lovato LC, et al.; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574
106. Keech A, Simes RJ, Barter P, et al.; FIELD study investigators. Effects of long-Term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-1861
107. Cannon CP, Blazing MA, Giugliano RP, et al.; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-2397
108. Takeshita Y, Takamura T, Honda M, et al. The effects of ezetimibe on non-Alcoholic fatty liver disease and glucose metabolism: A randomised controlled trial. Diabetologia 2014;57:878-890
109. Loomba R, Sirlin CB, Ang B, et al.; San Diego Integrated NAFLDResearch Consortium(SINC). Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 2015;61:1239-1250
110. Zein CO, Unalp A, Colvin R, Liu YC, McCullough AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol 2011;54:753-759
111. Goh GB, Pagadala MR, Dasarathy J, et al. Reninangiotensin system and fibrosis in non-Alcoholic fatty liver disease. Liver Int 2015;35:979-985
112. Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-To-moderate hypertension-Associated non-Alcoholic steatohepatitis. World J Gastroenterol 2009;15:942-954
113. Torres DM, Jones FJ, Shaw JC, Williams CD, Ward JA, Harrison SA. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, prospective, open-label trial. Hepatology 2011;54:1631-1639
114. Cusi K. Treatment of patients with type 2 diabetes and non-Alcoholic fatty liver disease: current approaches and future directions. Diabetologia 2016;59:1112-1120
115. Ratziu V, Massard J, Charlotte F, et al.; LIDO Study Group; CYTOL study group. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-Alcoholic fatty liver disease. BMC Gastroenterol 2006;6:6
116. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-854
117. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57:1441-1447
118. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ; Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7:1104-1112
119. Sumida Y, Yoneda M, Hyogo H, et al.; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 2011;46:257-268
120. Adams LA, George J, Bugianesi E, et al. Complex non-invasive fibrosis models are more accurate than simple models in non-Alcoholic fatty liver disease. J Gastroenterol Hepatol 2011;26: 1536-1543